Compare FOFO & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | CSBR |
|---|---|---|
| Founded | 2017 | 1985 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 91.0M |
| IPO Year | N/A | N/A |
| Metric | FOFO | CSBR |
|---|---|---|
| Price | $4.13 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 22.1K | 6.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | ★ $10.65 | $33.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.86 | $5.59 |
| 52 Week High | $68.00 | $11.16 |
| Indicator | FOFO | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 27.18 | 36.31 |
| Support Level | $3.90 | $6.53 |
| Resistance Level | $5.70 | $6.34 |
| Average True Range (ATR) | 0.58 | 0.39 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 5.90 | 6.07 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.